The short version of Cyclic AMP fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-11 and is reviewed periodically as new material appears.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Chymotrypsinogen is an inactive precursor (zymogen) of chymotrypsin, a digestive enzyme which breaks proteins down into smaller peptides. Chymotrypsinogen is a single polypeptide chain consisting of 245 amino acid residues. It is synthesized in the acinar cells of the pancreas and stored inside membrane-bounded granules at the apex of the acinar cell. Release of the granules from the cell is stimulated by either a hormonal signal or a nerve impulse, and the granules spill into a duct leading into the duodenum.
=== Active site === There are two distinct bi-lobed active site cavities located at the bottom edge of each monomer’s αβαβα core. Identical six-residue loops, which meet at the dimer interface, separate the two active sites from each other. The loops being with Thr132 in the active site and ends with a cis-peptide bond to Pro138. A Met137 residue plugs a hole in the other monomer’s active site. Therefore, the active site is buried except for a 16 Å CoA-binding tunnel that connects the catalytic surface to the outer surrounding milieu. The width of the tunnel is too narrow for the aromatic substrates and products that must pass through it, implying that there must be some dynamic mobility within and around the tunnel when placed in solution. The active site contains a conserved catalytic triad of Cys164, His303 and Asn336. These residues aid in multiple decarboxylation and condensation reactions, with Cys164 acting as the active site nucleophile. Phe215 and Phe265 are two other important amino acids that act as “gatekeepers” to block the lower protein of the opening between the CoA-binding tunnel and the active site cavity. This limits the access of water to the active site while accommodating substrates and intermediates of varying shapes and sizes. Phe215 also orients the substrates at the active site during elongation of the polyketide intermediate.
The Western blot is extensively used in biochemistry for the qualitative detection of single proteins and protein-modifications (such as post-translational modifications). At least 8–9% of all protein-related publications are estimated to apply Western blots. It is used as a general method to identify the presence of a specific single protein within a complex mixture of proteins. A semi-quantitative estimation of a protein can be derived from the size and colour intensity of a protein band on the blot membrane. In addition, applying a dilution series of a purified protein of known concentrations can be used to allow a more precise estimate of protein concentration. The Western blot is routinely used for verification of protein production after molecular cloning. Western blots are also used in medical diagnostics, e.g., in the HIV test and BSE-test. The confirmatory HIV test formerly employed a Western blot to detect anti-HIV antibody in a human serum sample. Proteins from known HIV-infected cells are separated and blotted on a membrane as above. Then, the serum to be tested is applied in the primary antibody incubation step; free antibody is washed away, and a secondary anti-human antibody linked to an enzyme signal is added. The stained bands then indicate the proteins to which the patient's serum contains antibody. A Western blot is also used as the definitive test for variant Creutzfeldt–Jakob disease, a type of prion disease linked to the consumption of contaminated beef from cattle with bovine spongiform encephalopathy (BSE, commonly referred to as 'mad cow disease').
Sources: en.wikipedia.org
{\displaystyle \Delta _{^{12}CH_{2}D_{2}}={\left({\frac {0.183798}{T}}\right)}-{\left({\frac {785.483}{T^{2}}}\right)}+\left({\frac {1056280.0}{T^{3}}}\right)+\left({\frac {9.37307\times 10^{7}}{T^{4}}}\right)-\left({\frac {8.919480\times 10^{10}}{T^{5}}}\right)+\left({\frac {9.901730\times 10^{12}}{T^{6}}}\right)}
== Medical uses == Posaconazole is used to treat invasive Aspergillus and Candida infections. It is also used for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory to other drugs such as itraconazole and fluconazole. Clinical evidence of efficacy in treatment of invasive disease caused by Fusarium species (fusariosis) is limited. Intravenous administration appears to be helpful in a mouse model of naegleriasis and the drug kills Acanthamoeba castellanii cysts in vitro. It has been used to treat mucormycosis (black fungus disease) caused by Rhizopus mold.
Nick Coatsworth is an Australian infectious diseases expert. He was Australia's deputy chief medical officer during the early years of the COVID-19 pandemic, when he regularly appeared in print and on radio and television to provide the public with information. He is Nine Network's medical expert and presents the television show Do You Want to Live Forever? with Tracy Grimshaw.
Sources: en.wikipedia.org
Parmotrema perlatum typically grows in areas with ample light, favouring neutral to slightly acidic-barked broad-leaved trees. It is commonly found on siliceous rocks and walls, as well as mossy coastal rocks, generally growing in places with moderate to strong sunlight. In the Great Smoky Mountains National Park in the United States, Parmotrema perlatum is especially abundant on branches in humid, high-elevation habitats. Similarly, in East Africa, it grows in the misty environments of inselbergs, montane forests, and Erica-dominated habitats, typically found between 1,400 and 3,100 m (4,600 and 10,200 ft) above sea level. The species is globally distributed, found in both temperate and tropical regions. It has been reported across numerous European countries including Austria, Belgium, the Czech Republic, France, Germany, Great Britain, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Scandinavia, Slovakia, Spain, and Ukraine. Although it is rare in Eastern Europe, it is widely distributed in both the Asian and European parts of Russia. Beyond Europe, it is also present in Macaronesia, Africa, Australia, North America, and South America. Its Asian distribution includes India, Japan, Taiwan, and South Korea. Although it has historically been recorded in Nepal and Sri Lanka, these reports are considered tentative due to shifting species concepts and possible confusion with the lookalike Parmotrema pseudonilgherrense.
=== Writing career === After writing several short stories, a novella and book reviews, his debut crime novel, Dead I Well May Be, was published by Scribner in 2003. The book was followed by two sequels in what would become to be known as the Michael Forsythe Trilogy. Alongside these, McKinty wrote the three books in his Lighthouse Trilogy, a series of science fiction young adult novels set in New York City, his native Ireland, and the fictional planet Altair. In 2008 McKinty moved with his family to Melbourne, Australia, to become a full-time writer. He found his greatest success and critical acclaim with the Sean Duffy series, following the eponymous Royal Ulster Constabulary Sergeant during The Troubles, beginning with 2012's The Cold Cold Ground. In 2019, the author made this comment about that novel: "It didn't sell very well, but it ended up getting the best reviews of my career. I got shortlisted for an Edgar, won a couple of awards, and so then that set me on that path for the next six years of reluctantly, kind of being dragged into writing about Northern Ireland in the 1980s". The third Duffy book, In the Morning I'll Be Gone, won the 2014 Ned Kelly Award for Best Novel. McKinty has been an especially astute observer of class in fiction. He also began working as a writer and reviewer for a number of publications including The Guardian, The Sydney Morning Herald, The Washington Post, The Independent, The Australian, The Irish Times and Harpers.
Brazil also fields the R3 Emergency Operation Ration (Portuguese: Ração Operacional de Emergência – R3), a 12-hour ration to be used in situations where cooked foods cannot be provided for all meals. The R3 ration is similar to the R2 and uses the same components, but contains less food. The bag is printed with the emblem of the Brazilian Army, "Emergency Ration R3 (12 hours)" (Portuguese: Ração de Emergência R3 (12 Horas)) and Menu information. Inside are 3 thin plastic bags: 2 meal bags and 1 accessory packet.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.